23 Feb Aspect Biosystems
Tamer Mohamed, Founder and CEO
April 28 | 4:15pm | Salone dei Cavalieri, Section 1
Vancouver, Canada
(Private)
Aspect Biosystems is a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) to transform the treatment of currently incurable diseases. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s AI-powered bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s BTTs are designed to replace, repair, or supplement biological function inside the body. The company’s current therapeutic pipeline is focused on metabolic and endocrine diseases such as diabetes, obesity, rare endocrine disorders, and liver diseases. Aspect has raised over US$260M in funding and is backed by leading tech-bio and strategic investors including Dimension, Novo Nordisk, and Radical Ventures. The company is advancing its pipeline through internal development and strategic collaborations, including its partnership with Novo Nordisk.
